Dendritic Cell Immunotherapy

Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(19): 245-52.

Su J, Dannull J, Coleman D et al. Immunological and clinical responses in metastatic renal cell cancer patients vaccinated with tumor RNA transfected dendritic cells. Cancer Research 2003; 63: 2127-33.

Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004; 199: 251-63.

Tumor-mediated Immunosuppression and Reversal

Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007; 13: 727s-732s.

Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14(20):6674-6682.

Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-57.

Arcelis™ Immunotherapy Platform

DeBenedette MA, Calderhead DM, Tcherepanova IY, Nicolette CA, Healey DG. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother 2011; 34(1):45-57.

DeBenedette MA, Calderhead DM, Ketteringham H et al. Priming of a novel subset of CD28+ rapidly expanding high avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent. J Immunol 2008; 181:5296-5305.

Calderhead DM, DeBenedette MA, Ketteringham H et al. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response. J Immunother 2008; 31(8):731-741.

Prognostic Factors in Metastatic RCC

Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1):289-296.

Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34):5794-5799.

Heng DY, Xie W, Harshman L et al. External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy. J Clin Oncol 29: 2011 (suppl;  abstr 4560).

AGS-003

T. Logan, A. Amin, V. Cohen, et al. A Phase 1/2 Study of AGS-003, a personalized immunotherapeutic evaluated in newly diagnosed metastatic renal cell carcinoma subjects.  2010 ASCO Genitourinary Cancers Symposium, San Francisco, CA (2010). Abstract # 379.

Figlin RA, Amin A, Dudek AZ,  et al. Improved overall survival (OS) in a phase 2 study combining personalized dendritic cell (DC) based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30, 2012 (suppl 5; abstr 348).

Sunitinib

Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115-124.